Effect of mesocaval interposition shunting and repeated sclerotherapy on blood levels of gastrointestinal regulatory peptides, amino acids, and lysosomal enzymes - A prospective randomised trial

Liver

Volumn 19, Issue 1, 1999, Pages 3-11

  Isaksson, Björn ^a   Hultberg, Björn ^a   Hansson, Lars ^a   Bengtsson, Finn ^a   Jeppsson, Bengt ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Amino acids; Hormonal peptides; Lysosomal enzymes; Mesocaval interposition shunt; Sclerotherapy

Indexed keywords

AMINO ACID; ARGININE; BETA GLUCURONIDASE; BETA N ACETYLHEXOSAMINIDASE; GASTRIN; GLUCAGON; HORMONE; INSULIN; ISOLEUCINE; LEUCINE; LYSOSOME ENZYME; PANCREAS POLYPEPTIDE; PEPTIDE; PEPTIDE HORMONE; PROLINE; SOMATOSTATIN; TYROSINE; VALINE; VASOACTIVE INTESTINAL POLYPEPTIDE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GASTRIN BLOOD LEVEL; GLUCAGON BLOOD LEVEL; HEPATIC ENCEPHALOPATHY; HUMAN; INSULIN BLOOD LEVEL; LIVER CIRRHOSIS; LIVER FUNCTION; MALE; MESENTERIOCAVAL ANASTOMOSIS; METABOLISM; PATIENT MONITORING; PORTAL HYPERTENSION; SCLEROTHERAPY; SHUNTING;

ADULT; AGED; AMINO ACIDS; BETA-N-ACETYLHEXOSAMINIDASE; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL HORMONES; GLUCURONIDASE; HEPATIC ENCEPHALOPATHY; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; LYSOSOMES; MALE; MIDDLE AGED; PORTASYSTEMIC SHUNT, SURGICAL; PROSPECTIVE STUDIES; RETREATMENT; SCLEROTHERAPY;

EID: 0032900017     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.1999.tb00002.x     Document Type: Article

References (31)

1. PUGH R N H, MURRAY-LYON I M, PIETRONI M C, WILLIAMS R. Transsection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-49.
2. ISAKSSON B, JEPPSSON B, BENGTSSON F, HANNESSON P, HERLIN P, BENGMARK S. Mesocaval shunt or repeated sclerotherapy: effects on rebleeding and encephalopathy - a randomized trial. Surgery 1995, 117; 5: 498-504.
3. THORELL J I, LARSON S M. Radioimmunoassay and related techniques. CV Mosby Company, St Louis, USA. 1978: 205-11.
4. VON SCHENK H, NILSSON O R. Radioimmunoassay of extracted glucagon compared with three non-extraction assays. Clin Chim Acta 1981; 109: 183-91.
5. HÅKANSSON R, AXELSSON J, EKMAN R, SUNDLER F. Hypergastrinaemia evoked by omeprazole stimulated growth of gastric mucosa but not of pancreas or intestines in hamster, guinea-pig and chicken. Regul Pep 1988; 23: 105-15.
6. WALLENGREN J, EKMAN R, SUNDLER F. Occurrence and distribution of neuropeptides in the human skin. An immunocytochemical and immunochemical study on normal skin and blister fluid from inflamed skin. Acta Derm Venereol 1987, 67: 185-92.
7. WALLENGREN J, MÖLLER H, EKMAN R. Occurrence of substance P, vasoactive intestinal peptide and calcitonin gene-related peptide in dermographism and cold urticaria. Arch. Dermatol Res 1987; 279: 512-15.
8. HULTBERG B, HÄGERSTRAND I, ISAKSSON A, JOELSSON B, MELEN K, ELSUFI M E. Source of increased serum increased beta-hexosaminidase in rat liver cirrhosis. Enzyme 1988; 40: 18-24.
9. SHERLOCK S. Diseases of the liver and the biliary system. 7th ed. 1985. Blackwell Scientific Publications. ISBN 0-632-01305.
10. MCCULLOUGH A J, GLAMOUR T. Differences in amino acid kinetics in cirrhosis. Gastroenterol 1993, 104, 6: 1865-85.
11. ELSAFI M E, HULTBERG B, ISAKSSON A, HÅGERSTRAND I, PRYTZ H, STENRAM U. Lysosymes and human liver disease: A biochemical and immunohistochemical study of Beta-hexosaminidase. Eur J. Clin Chem Clin Biochem 1994; 32: 669-973.
12. ELSAFI M E, HULTBERG B, HÅGERSTRAND I, ISAKSSON A, STENRAM U. Immunohistochemical demonstration of beta-hexosaminidase in cirrhotic and cholestatic human livers with a monoclonal antibody. Liver 1991; 11: 350-54.
13. HULTBERG B, ISAKSSON A, JOELSSON B, ALWMARK A, GULLSTRAND P, BENGMARK S. Pattern of serum beta-hexosaminidase in liver cirrhosis. Scand J Gastroenterol 1983; 18: 877-80.
14. PRIOETTO J, NANKERVIS A, ASCKEN P, PUDLEY F J, CARUSO G, ALFORD F P. Insulin resistance in cirrhosis: evidence for a receptor defect. Clin Endocrin 1984; 21: 677-88.
15. PETRIDES A S, GROOP L C, RIELY C A, DEFRONZO R A. Effect of physiologic hyperinsulinemia on glucose and lipid metabolism in cirrhosis. J Clin Invest 1991; 88: 565-70.
16. VANNINI P, FORLANI G, MARCHESINI G, CIAVARELLA A, ZOLI M, PISO E. The euglycemic clamp technique in patients with liver cirrhosis. Horm Metab Res 1984; 16: 341-43.
17. RIGGIO O, MERLI M, CANGIANO C, et al. Glucose intolerance in liver cirrhosis. Metabolism 1982; 31: 627-34.
18. SIRINEK K R, O'DORISIO T M, LEVINE B A. Glucose intolerance and hyperinsulinemia of cirrhosis are not results of spontaneous or surgical portosystemic shunting. Am J Surg 1991; 161: 149-53.
19. SMITH-LAING G, ORSKOV H, GORE M B, SHERLOCK S. Hyperglucagonemia in cirrhosis. Diabetologia 1980; 19: 103-8.
20. SHERWIN R, JOSHI P, HENDLER R, FELIG P, CONN HO. Hyperglucagonemia in Laennec's cirrhosis. N Engl J Med 1974; 290: 239-42.
21. LEWIS F W, ADAIR O, HOSSACK K F, EVERSON G T, WHITE J C, RECTOR W G JR. Plasma glucagon concentration in cirrhosis is related to liver function but not to portal-systemic shunting, systemic vascular resistance, or urinary sodium excretion. J Lab Clin Med 1991; 117: 67-75.
22. MORGAN J S, GROSZMANN R J. Somatostatin in portal hypertension. Dig Dis Sci 1989; 34 (S): 40-7.
23. LIMBERG B, KOMMERELL B. Correlation of altered plasma amino acid pattern in cirrhosis of the liver by somatostatin. Gut 1984; 25: 1291-95.
24. VERILLO A, DE TERESA A, MARTINO C, PINTO M, GOLIA R. Circulating somatostatin concentrations in healthy and cirrhotic patients. Metabolism 1986; 35: 130-35.
25. AVERGINOS A, DIMITRIOU-VOUDRI Y, ADAMOPOULOS A, PAPADIMITRIOU N, VOUDRIS B. Urinary gastrin output and serum gastrin in patients with liver cirrhosis. Urinary gastrin output in cirrhosis. Hepatogastroenterology 1994; 41: 445-48.
26. QUINTERO E, PIQUE J M, BOMBI J A, et al. Gastric mucosal vascular ectasies causing bleeding in cirrhosis. A distinct entity associated with hypergastrinemia and low serum levels of pepsinogen I. Gastroenterology 1987; 93: 1054-61.
27. LENZ H J, STRUCK T, GRETEN H, Koss M A, EYSSELEIN V E, WALSH J H, ISENBERG J I. Increased sensitivity of gastric acid secretion to gastrin in cirrhotic patients with portacaval shunts. J Clin Invest 1987; 79: 1120-27.
28. HENRIKSEN J H, STAUN-OLSEN P, BORG MOGENSEN N, FAHRENKRUG J. Circulating endogenous vasoactive intestinal polypeptide (VIP) in patients with uremia and liver cirrhosis. Eur J Clin Invest 1986; 16: 211-16.
29. GERAGHTY J G, ANGERSON W J, CARTER D C. Splanchnic haemodynamics and vasoactive agents in experimental cirrhosis. HPB Surg 1994, 8: 83-8.
30. SULLIVAN S N, CHASE R A, CHRISTTIFIDES N D, BLOOM S R, WILLIAMS R. The gut hormone profile in fulminant hepatic failure. Am J Gastroenterol 1981; 76: 338-41.
31. HERZ R, HALBFASS H J, RÖSSLE M, WALDMANN D. GEROK W. Mesocaval and distal splenorenal shunts: Effect on hepatic function, hepatic haemodynamics, and portal systemic encephalopathy. Klin Wochenschr 1985; 63: 409-18.